Skip to main content
Log in

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs

  • PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective: Debrisoquine hydroxylase (CYP2D6) is responsible for the oxidative metabolism of many clinically used drugs. Since this enzyme has been poorly studied in the southern part of Africa, we examined the CYP2D6 phenotypes and genotypes in 103 unrelated black Zimbabweans.

Methods:

Phenotyping for CYP2D6 activity was done using debrisoquine and metoprolol as probe drugs by measuring the urinary metabolic ratio (MR) of parent drug to metabolite concentration ratios. Genotyping was done using polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP), single-strand conformation polymorphism (SSCP) and sequencing analyses with respect to CYP2D6 variants of interest.

Results and conclusion:

Phenotyping with debrisoquine revealed two poor metabolisers (PMs), whereas 5 subjects out of 94 were PMs using metoprolol as probe drug. Genotypes predictive of the poor metaboliser status were observed for the two subjects who were PMs with both probe drugs, whereas no mutations could explain the PM phenotype for metoprolol among the three remaining subjects, a fact possibly explained by lack of compliance in metoprolol intake. There was a moderate correlation of 0.67 between the debrisoquine and metoprolol metabolic ratios in the 89 subjects who were extensive metabolisers for both probe drugs. The median values for the metabolic ratios for debrisoquine and metoprolol as probe drugs were 1.00 and 1.35, respectively, which are higher than those observed in Caucasian populations. This is indicative of a decreased capacity for metabolism of CYP2D6 substrates by Zimbabweans compared to Caucasians. Evaluation of the DNA samples for the known allelic variants CYP2D6A, CYP2D6B, CYP2D6C,CYP2D6D or CYP2D6Ch 1 yielded no explanation for these results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 4 February 1995/Accepted in revised form: 27 March 1996

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masimirembwa, C., Hasler, J., Bertilssons, L. et al. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. E J Clin Pharmacol 51, 117–122 (1996). https://doi.org/10.1007/s002280050170

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050170

Navigation